Lotus Pharmaceutical CoTPE:1795 -3.17%76 Dividend Yield % is 3.06% as of Jun. 27, 2026, which is 141% above its 10-year median of 1.27. GuruFocus rates TPE:1795 with a GF Score™ of 76/100 and a GF Value™ of NT$441.58 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 516 Drug Manufacturers companies, Lotus Pharmaceutical Co ranks better than 65.12% on this metric.
As of today (2026-06-27), the Trailing Annual Dividend Yield of Lotus Pharmaceutical Co is 3.06%.
Good Sign:
Lotus Pharmaceutical Co Ltd stock Dividend Yield % is close to 5-year high.
The historical rank and industry rank for Lotus Pharmaceutical Co's Dividend Yield % or its related term are showing as below:
TPE:1795'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.23 Med: 1.27 Max: 3.06
Current: 3.06
During the past 13 years, the highest Dividend Yield of Lotus Pharmaceutical Co was 3.06%. The lowest was 0.23%. And the median was 1.27%.
TPE:1795's Dividend Yield % is ranked better than 65.12% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.03
vs TPE:1795: 3.06
During the past 12 months, Lotus Pharmaceutical Co's average Dividends Per Share Growth Rate was 24.40% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 44.10% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Lotus Pharmaceutical Co was 136.80% per year. The lowest was 44.10% per year. And the median was 90.45% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Lotus Pharmaceutical Co (TPE:1795) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Pharmaceutical Co Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Lotus Pharmaceutical Co's Dividend Yield % falls into.
Lotus Pharmaceutical Co Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Lotus Pharmaceutical Co Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
TWD 5.778592
2025-08-11
2025-08-12
2025-09-05
Cash Dividend
annually
TWD:TWD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co (TPE:1795) has a Dividend Yield % of 3.06% as of Jun. 27, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Lotus Pharmaceutical Co and its competitors. This is 141% above median its historical median of 1.27. Over the past decade, Lotus Pharmaceutical Co's Dividend Yield % has ranged from 0.23 to 3.06. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #180 out of 516 companies in the Drug Manufacturers industry, placing it in the top 34.9%.
Is Lotus Pharmaceutical Co's Dividend Yield % too high?
Lotus Pharmaceutical Co's current Dividend Yield % of 3.06% is 141% above median its 10-year median of 1.27. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 3.06. The Drug Manufacturers industry median Dividend Yield % is 2.03. Lotus Pharmaceutical Co's value of 3.06% is 50.7% above this industry median. Based on the distribution chart, Lotus Pharmaceutical Co ranks #180 out of 516 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lotus Pharmaceutical Co has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #180 out of 516 companies for Dividend Yield %. This puts Lotus Pharmaceutical Co in the upper half of its industry. The industry median Dividend Yield % is 2.03. Lotus Pharmaceutical Co's value of 3.06% is 50.7% above this benchmark. Historically, Lotus Pharmaceutical Co's own Dividend Yield % has ranged from 0.23 to 3.06 over the past decade. While the company's 10-year median is 1.27 vs. the industry median of 2.03, Lotus Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.03, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Pharmaceutical Co's current Dividend Yield % of 3.06% is 50.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Lotus Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Pharmaceutical Co's current Dividend Yield % is 3.06%, which is 141% above median its own 10-year median of 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$441.58, compared to a current price of NT$183.00 — trading 58.6% below its estimated fair value. The current Dividend Yield % is 3.06%, which is 141% above median its 10-year median of 1.27 and 50.7% above the Drug Manufacturers industry median of 2.03. Lotus Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current Dividend Yield % is 3.06% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$183.00 is trading 58.6% below its estimated GF Value™ of NT$441.58.
GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for TPE:1795:
Dividend Yield %: 3.06% (141% above median its 10-year median of 1.27)
GF Value™: NT$441.58 vs. price of NT$183.00 (58.6% below fair value)
Industry Position: 50.7% above the Drug Manufacturers median (#180 of 516)
No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
76GF Score
Get the complete analysis for TPE:1795
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1795 has been successfully added to your 
